136 related articles for article (PubMed ID: 527209)
21. The prevention of methotrexate toxicity by thymidine infusions in humans.
Ensminger WD; Frei E
Cancer Res; 1977 Jun; 37(6):1857-63. PubMed ID: 870189
[TBL] [Abstract][Full Text] [Related]
22. 5-Fluorouracil and methotrexate administered simultaneously as a continuous infusion. A phase I study.
Lokich JJ; Phillips D; Green R; Paul S; Sonneborn H; Zipoli TE; Curt G
Cancer; 1985 Nov; 56(10):2395-8. PubMed ID: 4042072
[TBL] [Abstract][Full Text] [Related]
23. The pharmacokinetics of 7-hydroxymethotrexate following medium-dose methotrexate therapy.
Stewart AL; Margison JM; Wilkinson PM; Lucas SB
Cancer Chemother Pharmacol; 1985; 14(2):165-7. PubMed ID: 3971482
[TBL] [Abstract][Full Text] [Related]
24. Age-related pharmacokinetics of high-dose methotrexate in patients with osteosarcoma.
Wang YM; Sutow WW; Romsdahl MM; Perez C
Cancer Treat Rep; 1979 Mar; 63(3):405-10. PubMed ID: 284845
[TBL] [Abstract][Full Text] [Related]
25. [A pharmacokinetic study on high-dose methotrexate administration--the effects of volume changes of parenteral solutions on the elimination rate].
Yoshioka S; Tsukamoto T; Nakano M; Oka S; Nakano M; Norimatsu H
Gan To Kagaku Ryoho; 1994 Jan; 21(1):97-102. PubMed ID: 8291921
[TBL] [Abstract][Full Text] [Related]
26. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study.
Forastiere AA; Metch B; Schuller DE; Ensley JF; Hutchins LF; Triozzi P; Kish JA; McClure S; VonFeldt E; Williamson SK
J Clin Oncol; 1992 Aug; 10(8):1245-51. PubMed ID: 1634913
[TBL] [Abstract][Full Text] [Related]
27. The effect of prior cisplatin therapy on the pharmacokinetics of high-dose methotrexate.
Crom WR; Pratt CB; Green AA; Champion JE; Crom DB; Stewart CF; Evans WE
J Clin Oncol; 1984 Jun; 2(6):655-61. PubMed ID: 6539365
[TBL] [Abstract][Full Text] [Related]
28. Modulation of the antitumor effect of methotrexate by low-dose leucovorin in squamous cell head and neck cancer: a randomized placebo-controlled clinical trial.
Browman GP; Goodyear MD; Levine MN; Russell R; Archibald SD; Young JE
J Clin Oncol; 1990 Feb; 8(2):203-8. PubMed ID: 2405105
[TBL] [Abstract][Full Text] [Related]
29. Methotrexate treatment of advanced head and neck cancers: a dose response evaluation.
Woods RL; Fox RM; Tattersall MH
Cancer Treat Rep; 1981; 65 Suppl 1():155-9. PubMed ID: 7034929
[TBL] [Abstract][Full Text] [Related]
30. Phase II clinical trial with high-dose methotrexate therapy and citrovorum factor rescue.
Isacoff WH; Eilber F; Tabbarah H; Klein P; Dollinger M; Lemkin S; Sheehy P; Cone L; Rosenbloom B; Sieger L; Block JB
Cancer Treat Rep; 1978 Sep; 62(9):1295-304. PubMed ID: 356984
[TBL] [Abstract][Full Text] [Related]
31. Randomised phase II study of methotrexate (MTX) versus methotrexate plus lonidamine (MTX + LND) in recurrent and/or metastatic carcinoma of the head and neck.
Colella E; Merlano M; Blengio F; Angelini F; Ausili Cefaro GP; Scasso F; Lo Russo V; Cirulli S; Giannarelli D; Cognetti F
Eur J Cancer; 1994; 30A(7):928-30. PubMed ID: 7946585
[TBL] [Abstract][Full Text] [Related]
32. Early recognition of patients with decreased methotrexate clearance following high-dose methotrexate infusion therapy.
Ikeda H; Kihira K; Kuwata N; Arai S; Kimura Y; Miyake K; Kitaura T; Fujimura K; Kuramoto A; Fukuchi H
Hiroshima J Med Sci; 1996 Jun; 45(2):57-62. PubMed ID: 8810132
[TBL] [Abstract][Full Text] [Related]
33. Concepts in use of high-dose methotrexate therapy.
Treon SP; Chabner BA
Clin Chem; 1996 Aug; 42(8 Pt 2):1322-9. PubMed ID: 8697606
[TBL] [Abstract][Full Text] [Related]
34. A randomized comparison of high-dose infusion methotrexate versus standard-dose weekly therapy in head and neck squamous cancer.
Taylor SG; McGuire WP; Hauck WW; Showel JL; Lad TE
J Clin Oncol; 1984 Sep; 2(9):1006-11. PubMed ID: 6332178
[TBL] [Abstract][Full Text] [Related]
35. Randomized phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck: a European Organization for Research and Treatment of Cancer Head and Neck Cancer Cooperative Group study.
Schornagel JH; Verweij J; de Mulder PH; Cognetti F; Vermorken JB; Cappelaere P; Armand JP; Wildiers J; de Graeff A; Clavel M
J Clin Oncol; 1995 Jul; 13(7):1649-55. PubMed ID: 7602354
[TBL] [Abstract][Full Text] [Related]
36. Continuous methotraxate intra-arterial infusion in the treatment of head and neck cancer.
Losada JS
Med J Zambia; 1977; 11(3):73-4. PubMed ID: 899292
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetic study of methotrexate, folinic acid and their serum metabolites in children treated with high-dose methotrexate and leucovorin rescue.
Wolfrom C; Hepp R; Hartmann R; Breithaupt H; Henze G
Eur J Clin Pharmacol; 1990; 39(4):377-83. PubMed ID: 2076721
[TBL] [Abstract][Full Text] [Related]
38. [Clinical experiences with high-dose methotrexate].
Geissler K; Lenzhofer R; Schneeweiss B; Moser K
Wien Klin Wochenschr; 1984 May; 96(10):381-9. PubMed ID: 6475060
[TBL] [Abstract][Full Text] [Related]
39. [Effects of infusion duration of high-dose methotrexate on cerebrospinal fluid drug levels in lymphoma patients].
Lin XB; Zhou NN; Li S; Cai QQ; Xia ZJ; Liao H; Gao Y; Huang HQ
Ai Zheng; 2008 Oct; 27(10):1100-5. PubMed ID: 18851792
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics of methotrexate and 7-hydroxymethotrexate following infusions of high-dose methotrexate.
Breithaupt H; Küenzlen E
Cancer Treat Rep; 1982 Sep; 66(9):1733-41. PubMed ID: 6956440
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
